With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes and heart or kidney disease.

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Gadar 3 EXCLUSIVE: Sunny Deol says he ‘would love to play Tara Singh over and over again’; shares the reason behind it Did King helmer Siddharth Anand hint at reports of Deepika Padukone’s ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Quack cardiac surgeries, World Health Day policies, Trump's healthcare decisions, anti-obesity drug coverage, and more health ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...